These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 38314399)

  • 1. A Novel Case of CMV Resistance to Valganciclovir and Maribavir in a Renal Transplant Patient.
    Pearce H; Montgomery EK; Sheerin N; Ellam H
    Transpl Int; 2024; 37():11985. PubMed ID: 38314399
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluating Real-World Experience With Maribavir for Treatment of Refractory/Resistant Cytomegalovirus in Renal Transplant Recipients.
    Beechar VB; Phadke VK; Pouch SM; Mehta AK; Karadkhele G; Larsen CP; Woodworth MH
    Clin Transplant; 2024 Oct; 38(10):e15480. PubMed ID: 39427300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maribavir for Preemptive Treatment of Cytomegalovirus Reactivation.
    Maertens J; Cordonnier C; Jaksch P; Poiré X; Uknis M; Wu J; Wijatyk A; Saliba F; Witzke O; Villano S
    N Engl J Med; 2019 Sep; 381(12):1136-1147. PubMed ID: 31532960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of maribavir versus conventional antiviral therapies for post-transplant refractory cytomegalovirus infection with or without genotypic resistance: A US perspective.
    Schultz BG; Kotton CN; Jutlla G; Ressa R; de Lacey T; Chowdhury E; Bo T; Fenu E; Gelone DK; Poirrier JE; Amorosi SL
    J Med Virol; 2024 Apr; 96(4):e29609. PubMed ID: 38647051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Not Available].
    Loft JA; Riis PT; Schultz NA; Bjerrum S; Schønning K; Pedersen CR; Krohn PS; Nielsen SD
    Ugeskr Laeger; 2024 Apr; 186(15):. PubMed ID: 38708697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment for First Cytomegalovirus Infection Post-Hematopoietic Cell Transplant in the AURORA Trial: A Multicenter, Double-Blind, Randomized, Phase 3 Trial Comparing Maribavir With Valganciclovir.
    Papanicolaou GA; Avery RK; Cordonnier C; Duarte RF; Haider S; Maertens J; Peggs KS; Solano C; Young JH; Fournier M; Murray RA; Wu J; Winston DJ;
    Clin Infect Dis; 2024 Mar; 78(3):562-572. PubMed ID: 38036487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New Perspectives on Antimicrobial Agents: Maribavir.
    Halpern-Cohen V; Blumberg EA
    Antimicrob Agents Chemother; 2022 Sep; 66(9):e0240521. PubMed ID: 35916518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial.
    Avery RK; Alain S; Alexander BD; Blumberg EA; Chemaly RF; Cordonnier C; Duarte RF; Florescu DF; Kamar N; Kumar D; Maertens J; Marty FM; Papanicolaou GA; Silveira FP; Witzke O; Wu J; Sundberg AK; Fournier M;
    Clin Infect Dis; 2022 Sep; 75(4):690-701. PubMed ID: 34864943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral antiviral drugs for treatment of cytomegalovirus in transplant recipients.
    Razonable RR
    Clin Microbiol Infect; 2023 Sep; 29(9):1144-1149. PubMed ID: 36963566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-Dose Valganciclovir Prophylaxis Is Safe and Cost-Saving in CMV-Seropositive Kidney Transplant Recipients.
    Shi Y; Lerner AH; Rogers R; Vieira K; Merhi B; Mecadon K; Osband AJ; Bayliss G; Gohh R; Morrissey P; Farmakiotis D
    Prog Transplant; 2021 Dec; 31(4):368-376. PubMed ID: 34839729
    [No Abstract]   [Full Text] [Related]  

  • 11. Detection of Ganciclovir-Resistant Cytomegalovirus in a Prospective Cohort of Kidney Transplant Recipients Receiving Subtherapeutic Valganciclovir Prophylaxis.
    Wong DD; van Zuylen WJ; Novos T; Stocker S; Reuter SE; Au J; Foster CSP; Day RO; Horvath AR; Endre Z; Rawlinson WD
    Microbiol Spectr; 2022 Jun; 10(3):e0268421. PubMed ID: 35658598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Similar reduction of cytomegalovirus DNA load by oral valganciclovir and intravenous ganciclovir on pre-emptive therapy after renal and renal-pancreas transplantation.
    Kalpoe JS; Schippers EF; Eling Y; Sijpkens YW; de Fijter JW; Kroes AC
    Antivir Ther; 2005; 10(1):119-23. PubMed ID: 15751769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytomegalovirus infection in transplant recipients: newly approved additions to our armamentarium.
    Khawaja F; Spallone A; Kotton CN; Chemaly RF
    Clin Microbiol Infect; 2023 Jan; 29(1):44-50. PubMed ID: 35843567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytomegalovirus disease in high-risk transplant recipients despite ganciclovir or valganciclovir prophylaxis.
    Akalin E; Sehgal V; Ames S; Hossain S; Daly L; Barbara M; Bromberg JS
    Am J Transplant; 2003 Jun; 3(6):731-5. PubMed ID: 12780565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maribavir for Refractory or Resistant Cytomegalovirus Infections in Hematopoietic-cell or Solid-organ Transplant Recipients: A Randomized, Dose-ranging, Double-blind, Phase 2 Study.
    Papanicolaou GA; Silveira FP; Langston AA; Pereira MR; Avery RK; Uknis M; Wijatyk A; Wu J; Boeckh M; Marty FM; Villano S
    Clin Infect Dis; 2019 Apr; 68(8):1255-1264. PubMed ID: 30329038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Healthcare resource utilization of maribavir versus investigator-assigned therapy in transplant recipients with cytomegalovirus infection refractory (with or without genotypic resistance) to prior treatment: Exploratory analysis of the Phase 3 SOLSTICE trial.
    Hirji I; Cocks K; Moreno-Koehler A; Sundberg A
    Transpl Infect Dis; 2023 Jun; 25(3):e14064. PubMed ID: 37154528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maribavir: Mechanism of action, clinical, and translational science.
    Sun K; Fournier M; Sundberg AK; Song IH
    Clin Transl Sci; 2024 Jan; 17(1):e13696. PubMed ID: 38071422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of cytomegalovirus resistant to maribavir: real world, real problem?
    Kleiboeker HL; Prom A; Paplaczyk K
    Transpl Infect Dis; 2024 Apr; 26(2):e14259. PubMed ID: 38430481
    [No Abstract]   [Full Text] [Related]  

  • 19. EFFICACY OF MARIBAVIR IN VALGANCICLOVIR-RESISTANT CYTOMEGALOVIRUS RETINITIS.
    Tsui JC; Huang V; Kolomeyer AM; Miller CG; Mishkin A; Maguire AM
    Retin Cases Brief Rep; 2024 Mar; 18(2):164-167. PubMed ID: 36730596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Valganciclovir for the treatment of cytomegalovirus infections in pediatric intestinal transplant recipients: A case series.
    Henry M; Leick M; Florescu DF; Keck M
    Pediatr Transplant; 2021 Sep; 25(6):e14034. PubMed ID: 34081375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.